First and only PARP inhibitor to improve invasive disease-free survival in patients
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
AstraZeneca also played a critical role in the global response to COVID-19.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Subscribe To Our Newsletter & Stay Updated
